By Roshan Fernandez
Shares of Recursion Pharmaceuticals fell after the company reported a first-quarter loss.
Shares slid 13.4% to $4.94 during Monday's trading, and the stock is down 27% year to date.
The clinical stage biotechnology company reported a first-quarter loss of $202.5 million, or 50 cents a share, compared with $91.4 million, or 39 cents a share, a year earlier.
Analysts polled by FactSet were expecting a loss of 52 cents a share.
Revenue grew to $14.7 million from $13.8 million during the year-ago quarter. Analysts were expecting $15 million.
The Salt Lake City-based company said its research and development expenses rose to $130 million from $68 million during the year-ago quarter, driven primarily by an agreement with Tempus and a business combination with Exscientia.
Recursion had a cash position of $509 million as of March 31, compared with $603 million on Dec. 31, 2024.
Write to Roshan Fernandez at roshan.fernandez@wsj.com
(END) Dow Jones Newswires
May 05, 2025 12:21 ET (16:21 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.